AtaCor Medical Announces First Patient Treated Globally in its ALARION-EV Pivotal Trial
- Study will evaluate AtaCor’s investigational Atala™ lead in conjunction with Abbott’s investigational EV-ICD pulse generator
- Study will evaluate a novel parasternal extravascular ICD approach for the treatment of life-threatening ventricular tachyarrhythmias
SAN CLEMENTE, Calif., July 7, 2026 /PRNewswire/ — AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management, announced today the enrollment of the first patient in the company’s ALARION-EV study (NCT07324031). The trial evaluates an investigational next-generation parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system featuring AtaCor’s Atala™ lead in combination with an EV-ICD pulse generator developed by Abbott in patients who are indicated for a standard ICD but do not require chronic pacing therapy for slow heart rhythms.
